VorPembro: Vorasidenib and Pembrolizumab in Recurrent or Progressive IDH-1 Astrocytomas - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
CL1-95032-005: A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Glioma
Principal Investigator
Neuro-oncologist
Protocol Number
IRB:
PRO00111363
NCT:
NCT05484622
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment